Sarepta Therapeutics (SRPT) CRL Creates A Buying Opportunity - Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Sarepta Therapeutics (SRPT) PT Lowered to $181 at Baird
August 20, 2019 8:17 AM EDTBaird analyst Brian Skorney lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $181.00 (from $202.00) while maintaining a Outperform rating.
... More